Cetrorelix in reproductive medicine

This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian...

Full description

Saved in:
Bibliographic Details
Main Authors: Sebastian Findeklee, M.D., Ph.D (Author), Prof Klaus Diedrich (Author)
Format: Book
Published: Elsevier, 2023-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_5cce0ade5e714f339f72a37b51d6f223
042 |a dc 
100 1 0 |a Sebastian Findeklee, M.D., Ph.D.  |e author 
700 1 0 |a Prof Klaus Diedrich  |e author 
245 0 0 |a Cetrorelix in reproductive medicine 
260 |b Elsevier,   |c 2023-06-01T00:00:00Z. 
500 |a 2666-3341 
500 |a 10.1016/j.xfre.2022.11.012 
520 |a This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian stimulation treatment, its dosage, effects, and side effects are evaluated. The chapter terminates with a conclusion emphasizing the ease of use and the increase in patient safety because of a significantly reduced risk of ovarian hyperstimulation syndrome with cetrorelix compared with the agonist protocol 
546 |a EN 
690 |a Diseases of the genitourinary system. Urology 
690 |a RC870-923 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n F&S Reports, Vol 4, Iss 2, Pp 62-64 (2023) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2666334122001234 
787 0 |n https://doaj.org/toc/2666-3341 
856 4 1 |u https://doaj.org/article/5cce0ade5e714f339f72a37b51d6f223  |z Connect to this object online.